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  30 
Abstract 31 
 32 
Background. The introduction of metagenomic sequencing to diagnostic microbiology has 33 
been hampered by slowness, cost and complexity. We explored whether MinION nanopore 34 
sequencing could accelerate diagnosis and resistance profiling, using complicated urinary 35 
tract infections (UTIs) as an exemplar. Methods. Bacterial DNA was enriched from clinical 36 
urines (n=10) and from healthy urines ‘spiked’ with multi-resistant Escherichia coli (n=5), then 37 
sequenced by MinION. Sequences were analysed using external databases and bioinformatic 38 
pipelines or, ultimately, using integrated real-time analysis applications. Results were 39 
compared with Illumina data and resistance phenotypes. Results. MinION correctly identified 40 
pathogens without culture and, among 55 acquired resistance genes detected in the 41 
cultivated bacteria by Illumina sequencing, 51 were found by MinION sequencing directly 42 
from the urines; with 3 of the 4 failures in an early run with low genome coverage. Resistance-43 
conferring mutations and allelic variants were not reliably identified. Conclusions. MinION 44 
sequencing comprehensively identified pathogens and acquired resistance genes from urine 45 
in a timeframe similar to PCR (4 h from sample to result). Bioinformatic pipeline optimisation 46 
is needed to better detect resistances conferred by point mutations. Metagenomic-47 
sequencing-based diagnosis will enable clinicians to adjust antimicrobial therapy before the 48 
second dose of a typical (i.e. q8h) antibiotic. 49 
50 
Introduction 51 
The UK Prime Minister’s O’Neill Commission, reviewing the threat of antibiotic resistance1, 52 
stresses the potential of rapid diagnostics to improve both treatment and antibiotic 53 
stewardship. Reducing the time needed to obtain a microbiological diagnosis shortens the 54 
duration of broad empirical therapy and its selective pressures.  55 
PCR can detect pathogens and resistance genes in specimens without culture, but 56 
cannot cover the diversity of organisms and resistance determinants potentially present. 57 
Metagenomic sequencing could deliver this comprehensiveness2-7 but slow turnaround, cost 58 
and complexity have impeded introduction into clinical microbiology. 59 
 Oxford Nanopore’s MinION8 is the first technology potentially able to deliver 60 
sequencing data from clinical samples in a timeframe allowing early de-escalation and 61 
refinement of antimicrobial treatment. We examined its applicability to investigation of 62 
urinary tract infection (UTIs).  These account for over 8 million physician visits p.a. in the USA9. 63 
Most are trivial but, in severe cases, infection may ascend to the kidneys, with overspill to the 64 
bloodstream precipitating bacteraemia and urosepsis. Complicated UTIs are a growing cause 65 
of hospitalization, mostly of elderly patients10, and 35,676 Escherichia coli bloodstream 66 
infections were recorded in England in 2014-1511, over 60% with a urinary origin.  There is 67 
growing resistance, particularly in severe and bacteraemic infections, to fluoroquinolones, 68 
cephalosporins and lactamase-inhibitor combinations, driving use of previously-reserved 69 
carbapenems, even as ‘empirical’ therapy. With carbapenemases now proliferating, and few 70 
alternative therapies in reserve, escalating empiricism becomes increasingly untenable, 71 
underscoring the desirability of moving to early targeted therapy, guided by diagnostics. 72 
 73 
Materials and Methods 74 
Urines 75 
Ten heavily-infected (>107 cfu/mL) clinical urines (CUs 1-10) from patients at the Norfolk and 76 
Norwich University Hospital (NNUH) were tested. Additionally, urine from a healthy volunteer 77 
was spiked with 108 cfu/mL of multi-drug resistant E. coli strain H141480453, and with 78 
cultivated E. coli from CU6.  The genome sequence of E. coli H141480453 was determined 79 
previously (Illumina HiSeq) at Public Health England (PHE).  80 
 81 
Ethics 82 
Ethical approval was not required for the study as testing was performed, for method 83 
development purposes, on excess sample from routine clinical urines submitted to the NNUH 84 
clinical microbiology laboratory and no patient information was collected.  85 
 86 
Sample preparation for MinION Nanopore sequencing  87 
Methodology was refined during the project.  In its final iteration, urines (4-10 mL) were 88 
centrifuged at 300 g for 2 min to deplete human cells. The supernatant was collected and re-89 
centrifuged at 12,300 g for 5 min, with the resulting bacterial pellet resuspended in 1 mL of 90 
phosphate-buffered saline and processed with a MolYsis Basic 5 Kit (MolYsis Life Science, 91 
Bremen, Germany) to lyse residual human cells and to remove their DNA. Bacterial Lysis 92 
Buffer (Roche, Basel, Switzerland) and proteinase K (14-22 mg/mL) (Roche) were added and, 93 
after incubation for 10 min at 65°C, DNA was purified using the MagNA Pure Compact Nucleic 94 
Acid Isolation Kit (Roche) and DNA Bacteria v3_2 protocol. Variations, in early iterations, 95 
were: (i) the initial centrifugation was omitted and no human DNA depletion performed 96 
(CU1), and (ii) a NEBNext® Microbiome DNA Enrichment kit (New England BioLabs, Hitchin, 97 
UK) was used to remove human DNA instead of MolYsis (CUs 2-4). 98 
 To spike urines, 1 mL of overnight broth culture (109 cfu/mL) was added to 9 mL donor 99 
urine, which was then processed as above, always using the final iteration of the method. 100 
 The quality and concentration of DNA was assessed using a Qubit® 2.0 Fluorometer 101 
(Life Technologies, Paisley, UK), and 2200 TapeStation (Agilent Technologies, Santa Clara, CA); 102 
concentrations >15 mg/L were considered acceptable. 103 
 104 
MinION library preparation and sequencing 105 
To generate a library with an average fragment size of c.8 kb, up to 2 µg of DNA was 106 
fragmented by centrifugation at 7,200 rpm (3600 g) in a G-tube (Covaris, Brighton, UK), used 107 
according to manufacturer’s instructions, then end-repaired (New England BioLabs, Hitchin, 108 
UK), cleaned with Agencourt AMPure XP Beads (Beckman Coulter, High Wycombe, UK), and 109 
dA-tailed (New England BioLabs, Hitchin, UK). The product was re-cleaned, and eluted in 31 110 
μL TrisHCl pH 8.5.  111 
 The library was then prepared according to the SQK-MAP-006 Genomic Sequencing 112 
Kit protocol provided by Oxford Nanopore Technologies (ONT)12. Variations, in earlier library 113 
preparation experiments, were: (i) Kit SQK-MAP-002 was used for CUs 1-413; (ii) Kit SQK-MAP-114 
003 was used with CUs 5-6 and for spiked urine run 113; (iii) Kit SQK-MAP-004 was used14 for 115 
CU7 and urine spiked with E. coli recovered from CU6, (iv) Kit SQK-MAP-0058 was used with 116 
CUs 8-10 and  Spiked Urine Run 2, (v) ONT’s Rapid Sequencing Kit, with a-15 minute library 117 
preparation procedure, was used, in accordance with the manufacturer’s instructions, for 118 
Spiked Urine Run 4. 119 
MinION sequencing was performed using R7.3 flow cells, except for CUs 1-4, where 120 
R7.0 cells were used. Sequencing was run for 7.5 - 48 h (see Results Table 1). ONT’s MinKNOW 121 
software (versions 0.45.2.6 - 2.34.3) was used to collect raw electronic signal data, which were 122 
base-called using Metrichor™ software. 123 
BLAST and CARD identification of pathogens and resistance genes using MinION data 124 
Identification of species and resistance genes routinely utilised BLAST search and the CARD 125 
(Comprehensive Antibiotic Resistance Database) database 15. MinION data were extracted, in 126 
fasta format, from raw HDF5 files using Poretools16. BLAST database aliases were built for 127 
proteobacteria, firmicutes and human sequences. Top hits from each of these separate 128 
database aliases were identified. Taxa were distinguished using the in-house script 129 
blast_separate_taxa.pl, and taxonomy was assigned using blast_taxonomy_report.pl17 with 130 
some modifications18. 131 
Resistance genes were identified by aligning MinION reads to the CARD database using 132 
LAST, with parameters optimised for low-accuracy long matches19-21. Some sequences in 133 
CARD contain resistance-gene-flanking regions, leading to false positive results, therefore 134 
putative matches were verified by visualisation in Artemis (Sanger)22, 23 and by examination 135 
of the coordinates.  Consensus sequences were built upon the CARD database reference 136 
sequences using the MinION read alignments by Samtools 0.1.19, Samtools mpileup, bcftools, 137 
vcfutils.pl and vcf2fq, ultimately generating indexed Bam files 24, 25. BLASTn (BLAST v 2.2.30+) 138 
top hits were identified, using consensus sequences, against the CARD database, seeking 139 
>80% identity over the length of a gene. In addition, reciprocal BLAST best-hits were identified 140 
between the consensus sequences and the CARD database.  The resulting output data were 141 
parsed and sorted with a final report generated by a Python script18.  142 
 143 
WIMP and ARMA alignment for pathogen identification and resistance gene detection 144 
ONT’s ‘What’s In My Pot?’ (WIMP)26 Metrichor application identifies the uropathogen in real-145 
time, using a reference database and Kraken 11; along with Metrichor's Antimicrobial 146 
Resistance Mapping Application (ARMA)27 for real-time detection of antibiotic resistance 147 
genes. Both applications only became available toward the end of the study, and were used 148 
for Spiked Urine Run 3 only.  149 
 150 
Illumina library preparation  151 
Two methods were used to sequence DNA from the bacteria cultivated from the urines. At 152 
PHE’s Genomic Services Unit, genomic DNA was prepared using a GeneJET Genomic DNA 153 
Purification Kit (ThermoFisher, Cambridge, UK) and sequenced on a HiSeq instrument 154 
(Illumina, Cambridge, UK) in Rapid Run mode28. The library was prepared using the Nextera 155 
XT DNA Sample Preparation kits (Illumina), following the manufacturer’s protocol.  At Brunel 156 
University, bacterial DNA was quantified using the Quant-iT™ PicoGreen® dsDNA Kits (Life 157 
Technology, Paisley, UK) and a FLUOstar OPTIMA plate scanner (BMG Labtech, Ortenberg, 158 
Germany) according to manufacturers’ specifications. DNA (300 ng) was fragmented using an 159 
Episonic system (Epigentek, New York, USA). Libraries were constructed using the NEBNext 160 
Ultra DNA Sample Prep Master Mix Kit (NEB) using an automated protocol on a Biomek FX 161 
instrument (Beckman Coulter, High Wycombe, UK). Ligation was performed with Illumina 162 
Adapters (Multiplexing Sample Preparation Oliogonucleotide Kit) and ligated libraries were 163 
size-selected using Agencourt AMPure XP Beads (Beckman Coulter). Samples were sequenced 164 
on the 150-base paired-end Illumina HiSeq 2000 platform. 165 
 166 
CARD alignment for resistance gene detection from cultivated bacteria 167 
The presence of resistance genes in Illumina sequence reads was determined with 168 
‘Genefinder’, an in-house PHE algorithm that uses bowtie229 to map the reads to a local 169 
database of antimicrobial resistance genes, and Samtools 0.1.1824, 25 to generate an mpileup 170 
file. The script then parses the mpileup file to match to reference sequences, based on read 171 
coverage and > 90% nucleotide identity over full length of sequence (the lower threshold 172 
adopted for MinION was because of higher expected error rates). 173 
 174 
Phenotypic characterisation of uropathogens 175 
Bacteria were grown by standard methodology30 and identified by MALDI-TOF mass 176 
spectroscopy (Bruker, Bremen, Germany). Minimum inhibitory concentrations (MICs) were 177 
determined at PHE by British Society for Antimicrobial Chemotherapy agar dilution, with 178 
results categorised on EUCAST criteria31. 179 
 180 
Results  181 
MinION results and performance improvement 182 
Fifteen MinION runs were performed: 10 with CUs, four using urine spiked with  183 
E. coli H141480453 and one spiked with E. coli from CU6 (Table 1). Early attempts failed 184 
because human DNA was insufficiently depleted (CU1), flow cells were poor quality (CU2 and 185 
CU4) or DNA was degraded (CU3). Improved sample and library preparation, along with R7.3 186 
flow cells, resolved these issues (Fig. 1). From CU5 onwards, MinION produced 6536-34330 187 
2-D reads/run, with 2518-22405 "pass 2-D reads," and a mean read-length of 3452-6076 bp. 188 
The longest single read was 46213 bp, and single-read identity to reference sequences 189 
improved from 70% to 85%. Successive runs for urine spiked with E. coli H141480453 illustrate 190 
the gains (Fig 2); sequence yield and depth improved from Run 1 to 2; WIMP/ARMA software 191 
reduced processing to 7.5h in Run 3; this fell to 4h in Run 4 using the Rapid Library Preparation 192 
Kit, despite having to revert to BLAST/CARD analysis since WIMP/ARMA could not analyse the 193 
kits 1-D read data.  194 
 195 
Bacterial identification 196 
Analysis using BLAST and the CARD database was performed on 2-D "Pass" reads for CUs 5- 7 197 
and for all spiked urines (except Run 3, using WIMP/AMRA). For CUs 8-10 we combined 2-D 198 
reads from "Pass" and "Fail" folders. In all cases, MinION correctly identified the pathogen 199 
(Table 2); WIMP achieved this within 15 min.  Human DNA accounted for only 1.6-12.3% of 200 
reads, confirming that depletion was effective. Breadth of coverage was from 82.6-100%; 201 
depth was least for CU5 (2.71x) and greatest - 21.55-22.84x - for spiked urine Run 2 and CU8 202 
(Table 2). 203 
 204 
Resistance gene profiles 205 
Acquired resistance genes were readily identified in MinION outputs, as illustrated in Tables 206 
3 (Clinical Urines) and 4 (Spiked Urines). Among 55 acquired resistance genes detected by 207 
Illumina sequencing of the cultivated bacteria, 51 were found by MinION directly from urines; 208 
3 of 4 exceptions were with CU5, where coverage was poorest. Limitations were: (i) MinION 209 
often flagged multiple gene variants whereas Illumina definitively identified alleles, (ii) 210 
resistance-conferring mutations were not detected and (iii) plasmid and chromosomal ampC 211 
were not discriminated and nor could the mode of ampC expression be inferred. 212 
 213 
Clinical Urine 5 (K. pneumoniae) 214 
MinION and Illumina detected blaCTX-M-15 corresponding to the isolate’s ESBL phenotype.  Both 215 
also found blaOXA-1, congruent with amoxicillin-clavulanate resistance. Also in agreement, 216 
both found dfrA14, explaining trimethoprim resistance. Illumina identified blaLEN-12, and 217 
blaSHV-27, whereas MinION indicated blaSHV-32; these probably all correspond to the 218 
chromosomal blaLEN/blaSHV of K. pneumoniae. Illumina also detected blaTEM-1, which should 219 
not expand resistance in the presence of CTX-M-15. The strain was resistant to gentamicin 220 
and tobramycin, according with detection, by both MinION and Illumina, of aacC2; both 221 
methods also found aac6-1b-cr, encoding a tobramycin- and amikacin-modifying enzyme. The 222 
low amikacin MIC (2 mg/L) does not conflict with this: EUCAST advocates reporting all isolates 223 
with AAC(6’)-1b as amikacin non-susceptible irrespective of MIC. Streptomycin resistance 224 
agreed with the presence of strA (detected by both methods) and strB (found only by 225 
Illumina). Both approaches found qnrB and aac(6’)-1b-cr, according with low-level 226 
ciprofloxacin resistance (MIC, 2 mg/L). 227 
 228 
Clinical Urine 6 (E. coli) 229 
MinION and Illumina both found blaCTX-M-15 and blaOXA-1, again congruent with an ESBL 230 
phenotype and amoxicillin-clavulanate resistance. Both also indicated blaTEM-1. MinION 231 
flagged several acquired ampC genes whilst Illumina indicated blaCMY-113 and blaMIR-14, albeit 232 
below the 90% threshold.  It is likely that all these ampC calls really corresponded to E. coli 233 
chromosomal ampC, as the cefoxitin MIC for the isolate was only 8 mg/L, whereas cefoxitin 234 
MICs for E. coli with acquired plasmid AmpC enzymes are mostly >64 mg/L (PHE data on file).  235 
MinION and Illumina both found aacC2 and aac(6’)-1b-cr, agreeing with gentamicin and 236 
tobramycin resistance and a raised amikacin MIC. Both detected aadA5, but the organism 237 
was susceptible to streptomycin and this gene may not be expressed. Detection of dfrA17 by 238 
MinION and Illumina agreed with trimethoprim resistance. Double mutations in gyrA and 239 
parC, explaining high-level ciprofloxacin resistance, were detected by Illumina, not MinION.   240 
 241 
Clinical Urine 7 (E. coli) 242 
MinION and Illumina again detected blaCTX-M-15, agreeing with an ESBL phenotype; blaOXA was 243 
absent and the isolate was more susceptible than those from CUs 5 and 6 to penicillin-244 
inhibitor combinations. Both methods found blaTEM-1. Phenotypic resistance to streptomycin 245 
agreed with detection, by both methods, of aadA1/aadA3 and strA/strB; resistance to 246 
trimethoprim agreed with detection of dfrA1 by both techniques. An ampC gene (blaACT-24) 247 
was flagged by MinION, not Illumina. As with CU5, however, a low cefoxitin MIC (4 mg/L) 248 
contraindicated plasmid ampC, and the result probably reflected miscalling chromosomal 249 
ampC.  The ciprofloxacin MIC (0.25 mg/L) was slightly raised, and a single mutation in gyrA 250 
was detected by Illumina only.  251 
 252 
Clinical Urines 8 (E. coli) and 9 (E. cloacae) 253 
The E. coli from CU8 was resistant to ampicillin, amoxicillin-clavulanate and cefoxitin (MICs, 254 
16-64 mg/L), with diminished susceptibility to cefotaxime (MIC 1 mg/L). Cefotaxime-255 
cloxacillin synergy implied AmpC, as did the raised cefoxitin MIC (>64 mg/L).  MinION flagged 256 
several acquired ampC genes but these were not confirmed by Illumina sequencing, meaning 257 
that upregulation of chromosomal ampC is the likeliest explanation. CU9 contained E. cloacae 258 
with a cefotaxime MIC of 2 mg/L, reduced to 0.125 mg/L by cloxacillin, implying partial 259 
derepression of ampC, the commonest mode of oxyimino-cephalosporin resistance in this 260 
species.  MinION flagged multiple acquired ampC genes and Illumina flagged blaACT-24, all 261 
probably reflecting mis-calling of chromosomal Enterobacter ampC.  No other acquired genes 262 
were found in either CU8 or 9 in the isolates, agreeing with their general susceptibility. 263 
 264 
Clinical Urine 10 (K. pneumoniae) 265 
MinION and Illumina detected blaCTX-M-15 and blaOXA-1, agreeing with an ESBL phenotype and 266 
amoxicillin-clavulanate resistance. Both also found blaTEM. MinION additionally flagged 267 
multiple blaSHV/LEN variants whilst Illumina indicated blaSHV-28. High gentamicin, tobramycin 268 
and amikacin MICs (8-32 mg/L) accorded with detection of aacC2 and aac(6’)-1b-cr by both 269 
methods, with aacA4 additionally flagged by MinION. Resistance to streptomycin agreed with 270 
detection of strA and strB by both methods and aadA3 by MinION only. Trimethoprim 271 
resistance accorded with detection of dfrA14 by both techniques. qnrB and aac(6’)-1b-cr were 272 
found by both methods, but high-level ciprofloxacin resistance (>8 mg/L) more likely reflected 273 
gyrA and parC mutations, found only by Illumina.  274 
 275 
Spiked urines 276 
E.coli H141480453 had NDM and OXA-181 carbapenemases and was susceptible only to 277 
colistin and tigecycline. Synergy arose between EDTA and imipenem, reflecting metallo--278 
lactamase inhibition, but not between cephalosporins and clavulanate or cloxacillin. The four 279 
sets of MinION data, directly from urine, closely matched Illumina sequencing. Thus, blaTEM, 280 
blaCTX-M-group-1, blaOXA-48/181, blaNDM and blaCMY  β-lactamase were consistently identified, though 281 
with MinION flagging multiple matches within families whereas Illumina identified single 282 
alleles. Among aminoglycoside determinants, rmtB was consistently found by both methods, 283 
as were aacC2, aac(6’)-1b-cr and strA/B; Illumina found aadA2, aadA3 and aadA5 as did 284 
MinION run 3; MinION runs 1 and 2 flagged only one or two of these (aadA2 and aadA3 are 285 
closely related; aadA5 differs considerably). rmtB alone would confer pan-resistance to 286 
aminoglycosides, as observed. Trimethoprim resistance accorded with dfrA-12 and dfrA-17, 287 
found by Illumina and 3 of 4 MinION runs. aac(6’)-1b-cr and qnrS variants were consistently 288 
flagged by MinION and Illumina but mutations in chromosomal gyrA and parC –reliably 289 
detected by Illumina only- are more likely to explain observed high-level fluoroquinolone 290 
resistance. The organism was sulphonamide resistant, and Illumina detected sul1, while all 291 
MinION runs found both sul1 and sul2; tetracycline resistance agreed with detection of tet(A) 292 
by Illumina and in 3 of 4 MinION runs. catB3, congruent with observed chloramphenicol 293 
resistance, was consistently flagged by MinION; Illumina detected a related gene, but with 294 
only 69% identity to catB3, and a novel variant may be present. 295 
One hour of MinION sequencing delivered 0.2x, 3.75x, and 6.96x coverage depth for 296 
spiked Runs 1, 2 and 3, respectively (Fig. 3). To assess whether this detected resistance genes 297 
adequately, we reanalysed 1h reads from Runs 1-3 on ARMA software, and those of Run 4 298 
with BLAST/CARD (its 1-D reads were unsuitable for ARMA). All the acquired resistance genes 299 
identified in runs 2, 3 and 4 were recognisable in the 1h data, except for blaCMY in run 2 and 300 
strB in run 4. An ampC gene (blaLAT-1), was additionally identified in run 4. Lower coverage in 301 
Run 1 precluded 1-h detection of several genes.  302 
MinION sequencing of healthy urine spiked with E. coli from CU6 detected the same 303 
acquired genes as: (i) Illumina sequencing of the isolate, and (ii) MinION sequencing direct 304 
from CU6, confirming that any bacteria and resistance genes in the urinary tract of the healthy 305 
urine-donor did not distort results.  306 
 307 
Discussion 308 
Rapid pathogen profiling from clinical specimens, without culture, could facilitate better 309 
treatment and antibiotic stewardship. PCR diagnostics are under trial for this purpose but can 310 
only seek limited numbers of targets.  Sequencing could deliver a more comprehensive 311 
picture, and we investigated if this was achievable with the MinION. Urine was taken as an 312 
exemplar, with a heavy load of infecting bacteria, thereby: (i) yielding sufficient DNA for 313 
MinION sequencing, (ii) minimising the confounding effects of commensal bacteria and 314 
laboratory/reagent contamination on results and (iii) ensuring a high bacterial cell : human 315 
cell ratio. Hasman et al 7 previously applied Ion Torrent sequencing to urine, finding identical 316 
resistance genes as in the cultivated pathogens but, with a 24-h turnaround, their method 317 
only modestly accelerated conventional workflows.  318 
MinION can identify microorganisms32, 33 and MinION sequences can predict 319 
resistances in cultivated bacteria34, 35. Advantages over other sequencing platforms are: (i) 320 
rapid turnaround, (ii) low capital cost and (iii) small size. The technology remained under 321 
active development whilst the present studies were undertaken. The manufacturer's 322 
improvements, together with refinements in our sample preparation, delivered the stepwise 323 
gains illustrated in Fig. 1.  Initial experiments, without human cell depletion (CU1), led to a 324 
large proportion of human reads, and correspondingly low bacterial sequence yield.  We 325 
therefore sought to enrich bacterial DNA, initially by NEBNext® Microbiome DNA Enrichment 326 
(CUs 2-4), which proved unsatisfactory. From CU5, we combined differential centrifugation, 327 
removing most human cells, with MolYsis technology to lyse residual human cells and remove 328 
their DNA.  This allowed us to identify pathogens, and the same families of acquired resistance 329 
genes as found in pure cultures by Illumina, with good agreement to resistance phenotypes. 330 
Most sequence analysis was post-run, using BLAST search and CARD database.  331 
However the Metrichor WIMP and ARMA software, adopted late in these studies, allowed 332 
real-time analysis.  With this approach, adding together times for analysis (1h), sequencing 333 
(1h), library preparation (3h), DNA extraction and sample transport (2.5h) suggests a total 7-334 
8h turnaround, equating to one dosage interval for a 'typical' q8h antibiotic. Further 335 
acceleration is feasible using the 15-min library preparation kit (as with spiked urine Run 4) 336 
reducing turnaround to c. 4h (Fig. 3).  This is similar to PCR methodology, and would inform 337 
much earlier de-escalation and refinement of therapy than now. During the WIMP/ARMA-338 
based analysis c. 32 MB of 2-D sequencing data were generated, with almost 7x depth of 339 
coverage after 1h (57 MB of 2-D data with 11.37x depth were available after 2h). Based on 340 
Lander and Waterman's36 equation, we calculate that 7x depth covers 99.905% of the E. coli 341 
genome (4.6 MB), leaving little risk of missing an acquired resistance gene. Moreover, MinION 342 
sequencing error rates are diminishing rapidly (>90% identity with recent R9 pore 343 
chemistry)37. 344 
Although the approach has great potential, challenges remain:   345 
Firstly, we used heavily-infected urines (>107cfu/mL) to deliver the c.1 µg of DNA 346 
required for sequencing, whereas significant bacteriuria is defined as >105 cfu/mL. Low-input 347 
procedures have been described and should address this issue38; these reduce the DNA 348 
requirement for nanopore sequencing to 20 ng. 349 
Secondly, we tested one urine sample per flow cell. While this offers flexibility, it is 350 
expensive, with cells costing US$500-900 each.   This is balanced: (i) if a day's hospitalisation 351 
is saved, or (ii) if expensive antibiotics can be avoided.  Alternatively, Oxford Nanopore have 352 
introduced a PCR-free barcoding kit, allowing multiplexing of 12 samples; this would reduce 353 
the cost per sample but would necessitate batching, extending turnaround.   354 
Thirdly, allelic variants were poorly distinguished. In particular, the MinION-based 355 
pipeline (i) failed to detect mutations associated with fluoroquinolone resistance or ampC up-356 
regulation (likely to have been present, e.g. in the E. coli from CU8 and the E. cloacae from 357 
CU9); (ii) flagged multiple alleles (e.g. of blaTEM, blaSHV, blaCTX-M, blaNDM) whereas Illumina 358 
indicated single types, and (iii) confused acquired (plasmid-mediated) and endogenous 359 
chromosomal ampC and blaSHV/LEN.  Distinguishing blaNDM or blaCTX-M variants is unimportant, 360 
as all alleles have similar resistance implications; however, SNPs determine hydrolytic 361 
spectrum and inhibitor vulnerability within the TEM, SHV and GES families, thereby 362 
determining whether a therapy is appropriate or not.  In the case of AmpC, plasmid types are 363 
copiously expressed and have clear resistance association, whereas the implications of 364 
chromosomal types depends on their level of expression, which is determined by the 365 
promoter sequence in E. coli or by mutation of regulatory genes (principally ampD) in species 366 
with inducible ampC expression, e.g. E. cloacae.  To further complicate matters, the plasmid-367 
mediated types, which occur across species, are chromosomal escapes from other species – 368 
CMY-2, the commonest, is from Citrobacter freundii and DHA-1 from Morganella morganii.  369 
There are potential ways to address the challenges of distinguishing closely-related variants 370 
and predicting AmpC expression. SNPs and sequence variants can be called using MinION 371 
data,39 though this slow. In future, reads aligning to CARD could be isolated and polished to 372 
improve consensus accuracy, facilitating precise identification. What is more, long MinION 373 
reads can give context to the position of resistance genes, potentially enabling differentiation 374 
between plasmid-borne and chromosomal ampC genes. Optimally, MinION reads will enable 375 
the assembly of complete plasmids and in some cases, single reads will cover the full length 376 
of a plasmid. 377 
Fourthly, a gene may be present but fail to cause resistance, owing to poor expression, 378 
silencing or inactivation. MinION and Illumina found aadA5 in CU6 but the E. coli isolate was 379 
streptomycin susceptible.  Tyson et al.40 previously noted poorer genotype-phenotype 380 
concordance for streptomycin that for other resistances (81.3% versus 100%). 381 
Lastly, optimising the cut-off to only call ‘true positive’ results for resistance genes is 382 
challenging.  We used 90% identity for Illumina and (owing to lower base-calling accuracy) 383 
80% identity for MinION. This lower cut-off probably explains the larger number of 384 
misidentifications of plasmid ampC by MinION and the calling of catB3 in E. coli H141480453 385 
by MinION but not Illumina. A technical aspect, independent of MinION, was occasional 386 
misdetection of resistance genes due to inclusion of flanking regions of integrons in CARD 387 
(not shown). This might be resolved by adjusting cut-offs, but is better addressed by stricter 388 
database curation.  389 
 All the clinical urine samples tested in this study were infected with single pathogens. 390 
Polymicrobial UTIs were not sought, however MinION data can identify and differentiate 391 
multiple species in metagenomic samples41. Multiple strains of the same species would be 392 
harder to distinguish, but all their resistance genes would be represented in the sequence, 393 
whereas conventional culture would be liable to randomly select and test one of the strains 394 
present.  395 
 Given the improvements achieved already we believe that the technology can be 396 
enhanced to overcome these challenges. If so, MinION profiling from urosepsis patients could 397 
allow beneficial refinement of antibiotic regimens within the first dosage interval after clinical 398 
diagnosis.  399 
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Table 1. Clinical and spiked urines subjected to MinION sequencing in chronological order 
Sample and date 
Flow cell 
chemistry 
Sequencing time 
(h) 
Total number of 
reads 
Mean readlength 
(bp) 
Number  of 2-D 
reads 
Number  of 2-D 
'pass' reads 
Mean readlength 
of 2-D 'pass' (bp) 
Total number of 
2-D 'fail' reads 
Mean readlength 
of 2-D 'fail' (bp) 
CU1 09-07-2014 R7.0 24 12295 3647 1645 0 0 0 0 
CU2 12-07-2014 R7.0 24 8299 2859 621 0 0 0 0 
CU3 04-09-2014 R7.0 No results 
CU4 09-09-2014 R7.0 21 3829 1728 184 0 0 0 0 
Urine spiked 
with E. coli 
H141480453 run 
1; 06-11-2014 
R7.3 30 45652 2827 15216 10109(66%) 4103 5107 3880 
CU5 16-01-2015 R7.3 25.5 22968 3292 8191 2518(26.5%) 3980 5673 3491 
CU6 24-01-2015 R7.3 23 57289 4700 15932 12183(48%) 5510 3749 4848 
CU7 05-02-2015 R7.3 17.5 76499 4473 17050 10137(18.8%) 5414 9776 4447 
Urine spiked 
with E. coli from 
CU6 09-03-2015 
R7.3 14 56394 5419 13206 7678(27.9%) 6076 5528 5421 
CU8 02-03-2015 R7.3 33 86294 4664 20799 13798(36%) 5324 7001 4221 
CU9 30-03-2015 R7.3 26 28 767 4 926 6536 4376(29%) 5741 2160 4572 
CU10 16-05-2015 R7.3 35 141 511 3 107 34330 15074(23%) 3452 19256 2908 
Urine spiked 
with E. coli 
H141480453 run 
2; 04-05-2015 
R7.3 48 138 720 4 424 33589 17123(27.7%) 5013 16466 4040 
Urine spiked 
with E. coli 
H141480453 run 
3; 23-10-2015 
R7.3 7.5 97961 4308 28787 22405(77%) 4416 6382 2467 
Urine spiked 
with E. coli 
R7.3 29 21441 2043 - - - - - 
   
H141480453 run 
4; 26-01-2016 
Table 2. Pathogen identification using MinION sequencing for 6 clinical and spiked urines 
 
 
Clinical Urine 
5 
Clinical 
Urine 6 
Urine 
spiked with 
E. coli from 
CU6 
Clinical 
Urine 7 
Clinical 
Urine 8 
Clinical 
Urine 9 
Clinical Urine 
10 
Urine 
spiked with 
E. coli 
H141480453 
Run 1 
Urine 
spiked with 
E. coli 
H141480453 
Run 2 
Urine 
spiked with 
E. coli 
H141480453 
Run 3 
Reads used 2-D pass only 2-D pass 
only 
2-D pass 
only 
2-D pass 
only 
2-D pass and 
fail 
2-D pass and 
fail 
2-D pass and 
fail 
2-D pass 
only 
2-D pass 
only 
2-D pass 
only 
% non-human 
DNA reads 
matching 
Gram-negative 
bacteria 
76% 84% 83% 84% 81% 95% 85% 98% 89% - 
% DNA reads 
matching 
human 
6.6% 8.5% 8.5% 8.1% 12.3% 1.7% 9.7% 1.6% 4.2% - 
Best species 
match to 
MinION 
sequence data 
K. pneumoniae 
CG43 
E. coli 
JJ1886 
E. coli 
JJ1886 
E. coli PMV-
1 
E. coli 536 E. cloacae 
NCTC 9394 
K. pneumoniae 
CG43 
E. coli APEC 
O78 
E. coli APEC 
O78 
E. coli APEC 
O78 
Best species 
match to 
Illumina 
sequence data 
K. pneumoniae 
MGH 78578 
E. coli 
JJ1886 
E. coli 
JJ1886 
E. coli 
IHE3034 
E. coli 536 E. cloacae 
NCTC 9394 
K. pneumoniae E. coli ST410 E. coli ST410 E. coli ST410 
% Breadth of 
coverage to 
best match 
organism  
82.57% 99.59% 100% 92.19% 99.9% 86.25% 96.70% 95.13% 96.13% - 
Average depth 
of coverage 
versus best 
match 
organism 
2.71 x 15.65 x 10.58 x 10.77 x 22.84 x 9.16 x 17.61 x 7.25 x 21.55 x 21.51 x 
Run time (h)  25.5 23 14 17.5 36 26 35 30 48 7.5 
 
 
 
 Table 3. Genes found by MinION sequencing for 6 clinical urines compared with antibiotic MICs and Illumina sequencing for cultured isolates 
Urine and 
species 
Methoda 
Penicillins and 
inhibitor 
combinations 
Cephalosporins, monobactams and inhibitor combinations 
Fluoro-
quinolone 
Aminoglycosides Antifolate 
  Amp Aug Ptz Ctx Ctx-
clox 
Ctx-
clav 
Caz Caz-
clav 
Cpm Cpm-
clav 
Fox Azt Cip Amk Tob Gen Str Tmp 
CU5 K. 
pneumoniae 
MICs >64 16 8 128 64 ≤0.06 16 0.25 8 ≤0.06 4 16 2 2 16 32 R R 
MinION blaOXA-1 blaCTX-M-15, blaSHV-32 qnrB, 
aac(6’)-Ib-cr 
aac(6’)-Ib-cr, aacC2, strA dfrA14 
Illumina blaTEM-1, blaOXA-1 blaCTX-M-15, blaSHV-27, blaLEN-12 qnrB, 
aac(6’)-Ib-cr 
aac(6’)-Ib-cr, aacC2, strA, 
strB 
dfrA14 
CU6 E. coli MICs >64 16 4 128 32 ≤0.06 16 0.25 8 ≤0.06 8 32 >8 4 16 16 S R 
MinION blaTEM (mv*), blaOXA-1 blaCTX-M  gp1 (15),ampC(blaCMY mv*,  blaACC-4,  blaMIR-9, blaDHA-22) aac(6')-Ib-cr aac(6’)-Ib-cr, 
aacC2,aadA5 
dfrA17 
Illumina blaTEM-1, blaOXA-1 blaCTX-M-15 aac(6')-Ib-cr; 
gyrA 
(83:SL;87:D-
N); parC 
(80:S-I; 
84:E-V)  
aac(6’)-Ib-cr, 
aacC2,aadA5 
dfrA17 
CU7 E. coli MICs >64 8 2 128 32 ≤0.06 8 0.12 4 ≤0.06 4 16 0.25 2 1 0.5 R R 
MinION blaTEM (mv*) blaCTX-M  gr1,ampC (blaACT-24)  aadA1, aadA3,strA, 
strB 
dfrA1 
Illumina blaTEM-1 blaCTX-M-15 gyrA (83:S-
L) 
aadA1, strA, strB dfrA1 
CU8 E. coli MICs 64 32 4 1 ≤0.12 0.25 0.5 0.5 ≤0.12 0.12 >64 0.25 ≤0.12 1 0.5 0.5 S S 
MinION  ampC(blaCMY mv*, blaACC-4, blaMIR-4, blaDHA-6, blaFOX4)    
Illumina      
CU9 E. 
cloacae 
MICs >64 64 4 2 ≤0.12 2 1 1 ≤0.12 0.12 >64 0.25 ≤0.12 1 0.5 0.5 S S 
MinION  ampC (blaCMY mv*,blaACT-18, 24)    
Illumina  ampC (blaACT-24)    
CU10 K. 
pneumoniae 
MICs >64 32 >64 >256 256 0.125 128 1 64 ≤0.06 16 >64 >8 8 >32 >32 R R 
MinION blaTEM (mv*), blaOXA-1 blaCTX-M  gr1,  blaSHV(mv*), aac(6')-Ib-cr, 
qnrB 
aac(6')-Ib-cr, aacA4, 
aacC2, aadA3, strA, 
strB 
dfrA14 
Illumina blaTEM-1, blaOXA-1 blaCTX-M-15, blaSHV-28, blaLEN-12 gyrA (83:S-
I), parC 
(80:S-
I),aac(6')-Ib-
cr,qnrB 
aac(6')-Ib-cr, aacC2, 
strA, strB 
dfrA14 
 
Legend: AMP, ampicillin; AUG, amoxicillin-clavulanic acid; AZT, aztreonam; PTZ, piperacillin-tazobactam; CTX, cefotaxime;CTX-Clav, cefotaxime-
clavulanic acid, CAZ, ceftazidime; CAZ-Clav, ceftazidime-clavulanic acid; CPM, cefepime;CPM-Clav, cefepime-clavulanic acid; FOX, cefoxitin; CIP, 
ciprofloxacin; AMK, amikacin, TOB- tobramycin; GEN, gentamicin; STREP, streptomycin; TRIM, trimethoprim. All -lactamase inhibitors were 
used at 4 mg/L.                          (R): resistant;                        (I): intermediate;                       (S): susceptible based on EUCAST criteria; Black text: 
acquired genes found only by Illumina; White text: acquired gene families detected only by MinION; *mv: multiple (>5) different gene variants 
of this family flagged. 
a MICs are expressed as mg/L; MinION results are for the urine, tested directly; Illumina results are for the cultivated bacteria.  Only relevant 
genes are listed. 
bgyrA and parC were found in all clinical samples by both sequencing methods. They are only detailed when mutations were detected. 
Black textWhite text Black text
Table 4. Acquired resistance genes identified during four MinION runs for urine spiked with 
E. coli H141480453, compared with Illumina sequencing of the cultivated organism 
 
a-Lactamase gene variant detected e.g. here '1' means blaTEM-1 
*mv- multiple variants (> 5) flagged 
Grey: additional acquired genes detected only by MinION 
Acquired resistance genes in MinION runs 1, 2 and 4 were sought using BLAST and CARD 
searches, whereas in run 3 they were sought using ARMA software. 
Genes Illumina MinION run 1 (run 
time= 30 h) 
MinION run 2 
(run time= 48 
h) 
MinION run 3 ARMA 
(run time= 1 h) 
MinION run 4 
(run time= 1 h) 
-Lactamase genes 
blaTEM 1a 1, mv* 1, mv* 1, mv* 1, mv* 
blaCTX-M group-1 (15) group-1 (1, 3, 15, 52, 
114) 
group-1 (15, 
mv*) 
mv* not including 
blaCTX-M-15  
mv* not 
including blaCTX-
M-15 
blaOXA 1, 181 31 (=1,30), 181 2, 7, 30, 232 
(=181) 
1, 181, mv* 181, mv* not 
blaOXA-1 
blaNDM 4 4, 6, 7 4, 5, 7, 12, 13 1 mv* 
blaCMY 2 34, 45, 111 mv* not 
including 
blaCMY-2 
mv* not including 
blaCMY-2 
mv* not 
including 
blaCMY-2 
others - - - - blaLAT-1 
                                              Aminoglycoside resistance genes  
aacC aacC2 aacC2 aacC2 aacC2 aacC2, aacC8 
aadA2,aadA,
aadA5 
aadA2, aadA3, 
aadA5 
aadA2, aadA3 aadA5 aadA2, aadA3, aadA5, 
mv* 
mv* not 
including 
aadA2,A3, A5 
rmtB rmtB rmtB rmtB rmtB rmtA 
aac6’-1b-cr aac6’-1b-cr aac6’-1b-cr aac6’-1b-cr aac6’-1b-cr aac6’-1b 
strA/B strA/B strA/B strA/B strA/B strA 
                                                  Quinolone resistance genes  
qnr qnrS1 qnrS3 qnrS3, qnrS7 qnrS1 qnrS 
aac(6')-Ib-cr aac(6')-Ib-cr aac(6')-Ib-cr aac(6')-Ib-cr aac(6')-Ib-cr aac(6')-Ib 
                                                     Trimethoprim  resistance genes  
dfrA dfrA-12, dfrA-
17 
not detected dfrA-12, dfrA-
17 
dfrA-12, dfrA-17 dfrA7 (A17) , 
A12, A21, A22 
                                             Others  
cat not detected catB3 catB3 catB3 catB3/B6 
sul sul1 sul1, sul2 sul1, sul2 sul1, sul2 sul1, sul2 
tet tetA, tetR tetA, tetB, tetC tetE tetA, tetR tetA, tetR 
Fig. 1. Improvement of MinION sequencing performance and yields over 6h of sequencing run 
time 
 
 
 
Legend:  SU Spiked urine; CU clinical urine.  Runs are shown in chronological order, see Table 1. 
Grey total yields (1-D template + 1-D complement); Black total yields 2-D pass (bp); White total 
yields 2-D pass & fail (bp) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Timeline of coverage depth for successive runs with urine spiked with E. coli strain 
 
 
 
 
 
Legend: SU Run1, Spiked urine with multi-drug resistant E. coli H141480453 Run1;  SU  Run2, 
Spiked urine with multi-drug resistant E. coli H141480453 Run2; SU Run3, Spiked urine with 
multi-drug resistant E. coli H141480453 Run3.  
 
 
 
 
 
 
 
 
  
Fig. 3. Timeframe of MinION sequencing with the 15-min library preparation kit used in 
Spiked Urine Run 4 
 
 
 
 
 
 
 
 
 
 
 
